Pharmaceutical manufacturers of Favipiravir

Glenmark Pharmaceuticals Limited is a global pharmaceutical company based in Mumbai, India. The company focuses on developing and manufacturing generic and innovative drugs. Their therapeutic areas of expertise include dermatology, respiratory, and oncology. They also manufacture high-quality affordable generic products for the US and European markets through Glenmark Life Sciences, an independent unit of Glenmark Pharmaceuticals.

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

Egis Pharmaceuticals PLC is a prominent generic pharmaceutical firm engaged primarily in Central and Eastern Europe. The company's operations encompass all aspects of the pharmaceutical value chain from research and development to the manufacturing of APIs and final products, as well as sales and marketing in over 60 nations. Egis possesses extensive expertise in the advancement of value-added generic compounds, effective production processes, reliable analytical techniques for impurity determination, comprehensive understanding of organic chemical reactions, and robust IP support.

Aurore Life Sciences is a specialized manufacturer of active pharmaceutical ingredients (API) with a varied range of capabilities to enhance efficiency for generic pharmaceutical companies worldwide. Established in 2017 by a team with extensive expertise throughout the pharmaceutical supply chain, the company is dedicated to becoming the most favored partner for pharmaceuticals. At Aurore, we strive to innovate in the production and delivery of dependable high-quality products, earning the trust of both customers and regulatory bodies. Our focus on rapidly expanding capabilities has driven us to acquire, integrate, and extend our presence across multiple regions.

Optimus is one of the fastest-growing pharmaceutical companies with 16 years of experience in providing the best quality of API, Intermediates & Finished formulations in Global markets. Our aim from day one has been to provide and ensure better healthcare across the globe through our research, Innovations, affordable products & manufacturing excellence. Sekhmet Pharmaventures acquired major stake in Optimus Drugs Group of Companies in May 2022.

ZCL Chemicals Ltd operates as a 100% Export Oriented Unit (EOU) leveraging the potential of science and technology. It was founded in 1991, with its main office located in Mumbai. The R&D Center and cGMP-manufacturing facility is situated in the industrial hub of Ankleshwar city in Gujarat, approximately 300 kilometers north of Mumbai. This strategic location is well connected by Road, Rail, and Air, facilitating efficient cargo movement to the nearest major sea/airport, which is Mumbai. The company specializes in providing a diverse range of advanced fine chemical intermediates and actives.

Biophore, founded in 2007, has established itself as a dependable partner in the development and production of unique and intricate pharmaceutical products. With 4 USFDA and EU-certified API manufacturing facilities, a specialized intermediate facility, and a research and development laboratory accommodating 400 scientists, Biophore has positioned itself as a worldwide leader among API companies. It consistently ranks among the top 10 US DMF submitters and has acquired over 150 patents globally in process and polymorph areas. Biophore's facilities have an impressive history of successful inspections by regulatory authorities such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

CCSB has developed more than 30 bulk pharmaceutical products including Anti-Anxiety agent, Antidiabetics, Laxatives, Antifungals, Antihistamines, Antiseptics, Antiulcerants, Cardiovascular drugs, Skeletal, Muscle relaxants, Hypolipaemics, Antineoplastic, Antihyperlipedemia and Immunosuppresant. In 1984, CCSB was the first pharmaceutical manufacturer in Taiwan inspected and approved by FDA for cGMP compliance. CCSB has filed DMF's for 19 products with the FDA.

Zhejiang Hengkang Pharmaceutical Co. Ltd., was renamed from Zhejiang Sanmen Hengkang Pharmaceutical Co., Ltd. in December 2019.Hengkang is an emerging and fast-developing company, was established in 2004. Hengkang is specialized in active pharmaceutical ingredients development, GMP manufacturing and marketing，and it provides the most innovative intermediates and APIs to world-wide customers.

Lasa Supergenerics Limited ('Lasa') operates as an integrated group that covers the full animal and human healthcare value chain, ranging from discovery to delivery, and holds established expertise in research, production, and global marketing. Lasa group, a veterinary API manufacturing entity, was acquired in April 2012. The manufacturing facility of Lasa group is situated in Mahad, within the Konkan region of Maharashtra, specializing in 'catalyst chemistry' and producing anthelmintic/veterinary API products with the most extensive production capacities and product varieties in India.